October 08, 2026
Life Science Magazines About Us Contact Us
Life Science Newswire Service™ (LS)
Submit a Press Release
  • Analytical chemistry
  • Business
  • Biomanufacturing & bioprocessing
  • Biotechnology
  • Diagnostics
  • Drug development
  • More News
    • Environmental Science
    • Food & beverage
    • Forensic science
    • Healthcare
    • Hospitals
    • Lab tools
    • Materials science
    • Microbiology
    • Nanotechnology
    • Pharma & Biopharma
    • Pharmacy
    • Veterinary
    • Water Management
  • Press Releases
Reading: Insilico Medicine Raises More Than US$290 Million in Hong Kong’s Largest Biotech IPO of 2025
Share
Font ResizerAa
Life Science Newswire Service™ (LS)Life Science Newswire Service™ (LS)
Search
  • Business
  • Press Releases
  • Life Science Magazines
  • Life Sciences
    • Analytical chemistry
    • Biomanufacturing & bioprocessing
    • Biotechnology
    • Diagnostics
    • Drug development
    • Environmental Science
    • Food & beverage
    • Forensic science
    • Healthcare
    • Hospitals
    • Lab tools
    • Materials science
    • Microbiology
    • Nanotechnology
    • Pharma & Biopharma
    • Pharmacy
    • Veterinary
    • Water Management
  • About Us
  • Contact Us
  • Submit a Press Release
LS Newswire Service™ is part of GroupWeb Media Network. © 2025 GroupWeb Media LLC
Life Science Newswire Service™ (LS) > Blog > Life Sciences > Pharma & Biopharma > Insilico Medicine Raises More Than US$290 Million in Hong Kong’s Largest Biotech IPO of 2025
Pharma & Biopharma

Insilico Medicine Raises More Than US$290 Million in Hong Kong’s Largest Biotech IPO of 2025

By Newsroom
Last updated: January 4, 2026
1 Min Read
Share


  News

AI-driven drug discovery company Insilico Medicine raised approximately HKD 2.28 billion (more than US$290 million) in its initial public offering on the Hong Kong Stock Exchange today, marking the largest biotech IPO in the city this year.

#advertisement

Pharma Complience Management: A UK/EU Guide

Trading under the stock code 03696.HK, Insilico became the first company focused on AI-powered drug discovery to go public on the Main Board under Chapter 8.05…



Source link

Share This Article
Facebook Email Copy Link Print

HOT NEWS

EPA’s Final Rule on TCE: Regulatory Freeze and Further Delays

Environmental Science
April 5, 2025

المجموعة العربية للعناية بأمراض الكلى تدخل في استثمار استراتيجي يتجاوز 50 مليون دولار لدعم التوسع الإقليمي

AMMAN, Jordan — (ARAB NEWSWIRE)  — تدخل المجموعة العربية للعناية بأمراض الكلى (ARCG) مرحلة جديدة…

October 6, 2026

تُظهر الدراسة أن وجبة الإفطار الغنية بالجوز من الممكن أن تساعد في تعزيز قوة دماغك

California Walnut كما أظهر بحثٌ جديد أن تناول الجوز في وجبة الإفطار يمكن أن يحسّن…

April 5, 2025

Arab Newswire Provides Press Release Distribution in Arabic

Arab Newswire - Press release distribution to media in MENA/GCC Regions Newswire expands reach with…

April 5, 2025

YOU MAY ALSO LIKE

Epia Neuro Wants to Decode Brain’s Movement Intentions After Stroke

  News A San Francisco startup Epia Neuro launched today with a minimally invasive brain-computer interface (BCI) designed to help stroke…

Pharma & Biopharma
August 2, 2026

Insilico Medicine Files for Hong Kong IPO, Aims to Raise $292M

AI drug developer Insilico Medicine has returned to the Hong Kong public markets with an updated IPO prospectus, targeting about $292…

Pharma & Biopharma
December 21, 2025

$1B AI Drug Discovery Startup Xaira Therapeutics Appoints Foundation Model Expert Bo Wang as Head of Biomedical AI

Xaira Therapeutics, an AI-driven biotech launched in April 2024 with over $1 billion in funding, has appointed Dr. Bo Wang…

Pharma & Biopharma
April 5, 2025

BioNTech buys mRNA, courtroom rival CureVac in all-stock deal

Valued at $1.25 billion, the deal expands BioNTech’s cancer drug portfolio and heads off royalty costs it could have owed…

Pharma & Biopharma
June 13, 2025
Life Science Newswire Service™ (LS)

Contact Us

  • Whatsapp: +1 832-716-2363
  • Skype: Groupwebmedia
  • Telegram: Groupwebmedia

Share Us

About Us

Life Science Newswire Services (LS)™ aggregates, publishes and distributed news about the Life Science industry. In association with EmailWire, LS provides press release distribution services in the Life Science sector. Press releases are disseminated to journalists, experts, investors, trade publications and other related media outlets. For more information, contact us.

Categories

Analytical chemistry
Business
Biomanufacturing & bioprocessing
Biotechnology
Diagnostics
Drug development
Environmental Science
Food & beverage
Forensic science
Healthcare
Hospitals
Lab tools
Materials science
Microbiology
Nanotechnology
Pharma & Biopharma
Pharmacy
Veterinary
Water Management
Life Science Magazines
Press Releases

Recent News

المجموعة العربية للعناية بأمراض الكلى تدخل في استثمار استراتيجي يتجاوز 50 مليون دولار لدعم التوسع الإقليمي
October 6, 2026
AAPS PharmSci 360 Offers Fresh Insights for Industry Scientists
October 5, 2026
Congratulations to the 2026 ACS Fellows
October 5, 2026
Immunology Startup ai3Bio Aims to Redefine What It Means to Reset the Immune System
October 5, 2026

Life Science Magazines

A New Blueprint: Innovations in DNA Synthesis
July 7, 2026
Inside HCP Decision-Making – The 2026 Access Landscape
July 6, 2026
Checklist for Submitting to an Institutional Review Board
July 2, 2026
Unlocking the Power of Primary Care in Cronic Disease Research
July 2, 2026

LS Newswire Service™ is part of GroupWeb Media Network. © 2026 GroupWeb Media LLC

Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?